Page last updated: 2024-08-25

rosiglitazone and febuxostat

rosiglitazone has been researched along with febuxostat in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
McLean, L; Naik, H; Palmer, R; Wu, JT	1

Reviews

1 review(s) available for rosiglitazone and febuxostat

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

1 trial(s) available for rosiglitazone and febuxostat

Article	Year
The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate. British journal of clinical pharmacology, 2012, Volume: 74, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Analysis of Variance; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Biotransformation; Cross-Over Studies; Cytochrome P-450 CYP2C8; Double-Blind Method; Drug Interactions; Febuxostat; Female; Gout Suppressants; Half-Life; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Rosiglitazone; Substrate Specificity; Thiazoles; Thiazolidinediones; Young Adult	2012

Article

Year

The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.

British journal of clinical pharmacology, 2012, Volume: 74, Issue:2

Topics: Administration, Oral; Adolescent; Adult; Analysis of Variance; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Biotransformation; Cross-Over Studies; Cytochrome P-450 CYP2C8; Double-Blind Method; Drug Interactions; Febuxostat; Female; Gout Suppressants; Half-Life; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Rosiglitazone; Substrate Specificity; Thiazoles; Thiazolidinediones; Young Adult

2012

Other Studies

1 other study(ies) available for rosiglitazone and febuxostat

Article	Year
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013

Article

Year

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013